By proceeding, you agree to our Terms of Use and Privacy Policy.
Deepen Scientific Understanding of Inflammatory & Fibrotic ILDs, Investigate Biomarkers to Stratify Trial Populations and Identify Endpoints Which are Likely to Predict Clinical Success in Your Next Clinical Trial 2022 dawned with an exhilarating update from aTyr pharma that the FDA has granted orphan drug designation for ATYR1923 for the treatment
The event will address - new therapies, overcoming challenges with inhaled drug delivery and biomarkers for ILD clinical trials to enhance treatment.
With 20+ speakers and 150+ drug developers, uncover the secrets behind developing industry defining ILD therapies to supercharge drug development.
Networking with life sciences and drug development experts will help you scale your research and trials to deliver therapeutic strategies against ILDs.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
At Boehringer Ingelheim we create value through innovation with one clear goal: to improve the lives of patients. We develop breakthrough therapies and innovative healthcare solutions in areas of unmet medical need for both humans and animals.
Vitalograph is a global leader in respiratory diagnostics. We manufacture and supply high quality spirometers and medical devices which aid the detection, diagnosis and management of respiratory conditions.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.